Towards evidence-based response criteria for cancer immunotherapy

Early detection of immunotherapy-induced tumor response is of major benefit for patients but can be complicated by therapy-induced pseudoprogression. A consensus guideline-iRECIST- was developed as a modification of Response Evaluation Criteria in Solid Tumours (RECIST version 1.1). Here we describe...

Descripción completa

Detalles Bibliográficos
Autores principales: Garralda, Elena, Laurie, Scott A., Seymour, Lesley, de Vries, Elisabeth G. E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10209139/
https://www.ncbi.nlm.nih.gov/pubmed/37225715
http://dx.doi.org/10.1038/s41467-023-38837-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10209139/
https://www.ncbi.nlm.nih.gov/pubmed/37225715
http://dx.doi.org/10.1038/s41467-023-38837-3

Ejemplares similares